Abstract: Autism spectrum disorder (ASD) is the fast growing neurodevelopmental disorder worldwide. No biomarker tests for ASD currently exist. Research efforts in metabolomic may shed light on potential biomarkers for ASD. Here, we will review the current progress in metabolomics in early screening and diagnosis of ASD and focus on its effectiveness and caveats in clinical practices. This editorial also includes thoughtful discussion of future directions to provide better guidance for research in this area.